Hypoglycemic Effet Of Some Fluoroquinolones On Normal And Diabetic Experimental Animals
Abstract
Background:Fluoroquinolones are among the anti-microbial that have widespread use for treatment of community- and hospital-acquired infections. Although uncommon, hypoglycemia has been reported with some fluoroquinolones and appears to occur most frequently in elderly patients with type 2 diabetes mellitus who were receiving therapy with oral hypoglycemics. The clinical data emerged suggest that the fluoroquinolones can affect glucose homeostasis through an unknown mechanism. The present work aimed to explore the potential effects of some fluoroquinolones on glucose metabolism and blood glucose level in experimental animals. Two fluoroquinolones (gatifloxacin, moxifloxacin) were used in the present study using different rabbit groups; normal and experimentally diabetic. Dug interaction with anti-diabetic drugs was also investigated. Safety considerations were our goal. Materials And Method: In the present work, alloxan (100 mg / kg body weight 3 successive doses, intraperitonially) was used to induce diabetes in experimental animals. The blood glucose level after alloxan was measured. Oral anti-diabetics glimepiride, rosiglitazone, and metformin produced significant lowering effect on blood glucose level in normal and diabetic animals. Gatifloxacin and moxifloxacin were similar in producing lowering of blood glucose level in non diabetic and diabetic animals and significantly potentiated the hypoglycemic action of oral anti-diabetics in the alloxan diabetic rabbits.
Read the paper
Related studies
- Deciphering the Resistome of the Widespread Pseudomonas aeruginosa Sequence Type 175 International High-Risk Clone through Whole-Genome Sequencing
- Laboratory-based nationwide surveillance of antimicrobial resistance in Ghana
- Phenotypic characterization of an international Pseudomonas aeruginosa reference panel: strains of cystic fibrosis (CF) origin show less in vivo virulence than non-CF strains
- Incidence and factors associated with development of phlebitis: results of a pilot study cohort
- Efficacy of triple therapy with a proton pump inhibitor, levofloxacin, and amoxicillin as first-line treatment to eradicate Helicobacter pylori
- Ten-Day versus 14-Day Levofloxacin-Containing Triple Therapy for Second-Line Anti-Helicobacter pyloriEradication in Taiwan
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.